FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

Web Exclusives - Bladder Cancer, FDA Updates, Immunotherapy

On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda). If approved, the drug would be indicated as monotherapy to treat patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer who are ineligible for or have decided not to undergo cystectomy.

The filing was based on data from the multicenter, open-label, single-arm, phase 2 KEYNOTE-057 clinical trial of 102 patients (median age, 73 years) with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who were ineligible for or had decided not to undergo cystectomy.

Major efficacy outcome measures were complete response and duration of response. Patients received 200 mg of pembrolizumab every 3 weeks for up to 24 months or until unacceptable toxicity, progressive disease, or detection of persistent or recurrent high-risk non–muscle-invasive bladder cancer.

It is estimated that >80,000 new cases of bladder cancer will be diagnosed in 2019 in the United States. Approximately 75% of these patients are diagnosed with non–muscle-invasive bladder cancer, which means that the cancer cells have not grown into the main muscle layer of the bladder. Patients with high-grade non–muscle-invasive bladder cancer are at high risk for developing muscle-invasive and metastatic disease.

Keytruda was previously approved as a single agent or in combination with other agents for several other types of cancer, including melanoma, Merkel-cell carcinoma, lung cancer, hepatocellular carcinoma, head and neck cancer, Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, cervical cancer, and renal-cell carcinoma.

In a press release, Merck stated that its application will be reviewed by the FDA’s Oncologic Drugs Advisory Committee on December 17, 2019, and that it anticipates a Prescription Drug User Fee Act, or target action date, in January 2020.

Related Items
Inrebic Receives FDA Approval for Adults with Myelofibrosis
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer
Web Exclusives published on December 2, 2019 in FDA Updates
Keytruda plus Lenvima Combo FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
November 18, 2019 — Oncology News & Updates
Web Exclusives published on November 18, 2019 in Drug Updates, FDA Updates, Hepatocellular Carcinoma, In the News, Lymphoma
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
FDA News
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in FDA Updates
Nubeqa New Oral Therapy FDA Approved for Nonmetastatic Prostate Cancer
Web Exclusives published on October 29, 2019 in FDA Updates
Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor
Web Exclusives published on October 29, 2019 in FDA Updates
Last modified: December 5, 2019